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Abstract
Background—While methods for generating cardiomyocytes (CMs) from pluripotent stem cells
(PSCs) have been reported, current methods produce heterogeneous mixtures of CMs and non-CM
cells. Here, we report an entirely novel system in which PSC-derived CMs are purified by CM-
specific molecular beacons (MBs). MBs are nano-scale probes that emit a fluorescence signal
when hybridized to target mRNAs.
Method and Results—Five MBs targeting mRNAs of either cardiac troponin T or myosin
heavy chain 6/7 were generated. Among five MBs, a MB targeting myosin heavy chain 6/7
mRNA (MHC1-MB) identified up to 99% of HL-1 CMs, a mouse CM cell line, but < 3% of four
non-CM cell types in flow cytometry analysis, indicating that MHC1-MB is specific for
identifying CMs. We delivered MHC1-MB into cardiomyogenically differentiated PSCs through
nucleofection. The detection rate of CMs was similar to the percentages of cardiac troponin T
(TNNT2) or cardiac troponin I (TNNI3)-positive CMs, supporting the specificity of MBs. Finally,
MHC1-MB-positive cells were FACS-sorted from mouse and human PSC differentiating cultures
and ~97% cells expressed TNNT2- or TNNI3 determined by flow cytometry. These MB-based
sorted cells maintained their CM characteristics verified by spontaneous beating,
electrophysiologic studies, and expression of cardiac proteins. When transplanted in a myocardial
infarction model, MB-based purified CMs improved cardiac function and demonstrated significant
engraftment for 4 weeks without forming tumors.
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Conclusions—We developed a novel CM selection system that allows production of highly
purified CMs. These purified CMs and this system can be valuable for cell therapy and drug
discovery.
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Introduction
Human pluripotent stem cells (hPSCs), which include embryonic stem cells (hESCs) and
induced pluripotent stem cells (hiPSCs), have emerged as a promising therapeutic option for
repairing cardiac damage. While various methods for differentiating CMs from hPSCs have
been developed1-3, without purification, these systems can only generate mixed populations
with undifferentiated cells or non-CMs which may elicit adverse outcomes4, 5. Hence, one of
the major challenges confronting the clinical use of hPSC-derived CMs is the development
of efficient isolation techniques that allow enrichment of purified CMs.
Diverse approaches have been attempted to purify CMs from differentiating PSC cultures.
Genetic approaches using a fluorescent reporter gene driven by a cardiac promoter such as
NKX2.56, ISL17 or αMHC8 were reported to efficiently isolate CMs and/or cardiac
progenitor cells, but require genetic modification and therefore are incompatible with
clinical use. Another approach using a Percoll gradient capitalized on the specific density of
CMs2, 9; due to its crudeness, however, the maximal purity of the cells reported was only
53% 10. Sorting cells by surface proteins for progenitor cell markers such as KDR 11 or
PDGFRA 12 isolated cardiac progenitors but resulted in a mixture of CMs together with
endothelial and smooth muscle cells. Fluorescence activated cell sorting (FACS) after
application of the fluorescent mitochondrial dye tetramethylrhodamine methyl ester
perchlorate (TMRM) allowed cells with high mitochondrial density such as mature CMs to
take up the dye and become amenable for cell sorting13. However, as the dye reacts with
undifferentiated PSCs and does not detect most of the immature CMs14, concerns were
raised about specificity and sensitivity. Recently, studies identified two surface proteins
expressed on hPSC-derived CMs, SIRPA6, 14, and VCAM-16, 15 and used them for
enriching populations of CMs by cell sorting. However, these proteins are not specifically
expressed in CMs. For example, SIRPA is more highly expressed in the brain and the lung
than the heart and is only useful for a certain stage of CMs, raising concerns about its
effectiveness for purification14.
Accordingly, we aimed to develop a novel strategy to purify CMs from differentiating PSCs
by targeting genes that are specifically expressed in CMs. We hypothesized that molecular
beacons (MBs) hybridized to CM-specific mRNAs could enable isolation of CMs from a
mixed population16. This method can be applied for both basic research and clinical
applications. MBs are dual-labeled antisense oligonucleotide nano-scale probes with a
fluorophore at one end and a quencher at the other end17, 18 (Figure 1A). MBs are designed
to form a stem-loop (hairpin) structure in the absence of a complementary target so that
fluorescence of the fluorophore is quenched. However, hybridization with the target mRNA
opens the hairpin and separates the reporter from the quencher, allowing emission of a
fluorescence signal (Figure 1B). MB technology has been tested in a variety of cell types to
detect mRNA at various levels of expression and has been demonstrated to not alter the
expression level of target genes18. We have previously demonstrated the use of MBs for
detecting mESCs by simultaneous targeting of intracellular Oct4 mRNA and surface
markers19. While these studies did not attempt to isolate target cells, they suggest that MB
technology has unique potential for enriching target cells. In the present study, we first
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developed protocols to differentiate mouse and human PSCs into CMs and devised a
strategy to isolate CMs by applying MBs targeting CM-specific mRNAs followed by FACS
sorting (Figure 2). Our results suggest the possibility of purifying CMs at high efficiency
and specificity from hPSC differentiation cultures with this innovative and clinically
compatible purification system. These purified CMs are functional in vitro and in vivo.
Materials and Methods
The details concerning the materials and methods can be found in the online Data
Supplements.
Mouse ESC culture and differentiation
mESCs (J1) were maintained as described20. To differentiate mESCs into cardiac lineage, an
embryoid body (EB) method was employed with some modifications21.
Human PSC Culture and Differentiation
hESC (H1) were obtained from WiCell Research Institute (Madison, WI) and hiPSC (BJ1-
iPS10) was provided by George Daley at Harvard University22. The use of hPSCs was
approved by Emory University Human Embryonic Stem Cell Oversight Committee. These
undifferentiated hPSCs were cultured as described previously23. To direct the differentiation
of hPSCs to the cardiac lineage, we designed a staged protocol that is divided into four
distinct phases
Molecular beacon synthesis and characterization
Five MBs were synthesized by MWG Operon using standard resin-based synthesis methods
with HPLC purification (Table 1)18, 19, 23.
HL-1 cell culture 24
Nucleofection 25
Human heart tissue Flow cytometry and FACS-sorting 26
Immunocytochemistry and Immunohistochemistry 26
Real-time RT-PCR (Table 2) 26
Intracellular calcium (Ca2+) imaging 27
Action potential measurement 23
Induction of myocardial infarction (MI) and cell transplantation
All animal experiments were approved by Emory University IACUC. Myocardial infarction
(MI) and cell implantation were performed as we described previously28. We randomly
assigned the mice into three groups which received saline (PBS) (N = 10), 2 × 105
unpurified CMs differentiated from mESCs (N = 12), or 2 × 105 purified CMs with MHC1-
MB from differentiated mESCs (N = 11).
Echocardiography29
Statistical analyses—The authors have full access to and take full responsibility for the
integrity of the data. All authors have read and agreed to the manuscript as written.
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Results
Cardiomyocyte-specific molecular beacon generation
To determine optimal candidate genes detectable by MBs, we performed quantitative
reverse transcriptase PCR (qRT-PCR) analysis on known cardiac specific genes using
mRNAs extracted from freshly isolated mouse adult CMs (Supplementary figure 1a), human
neonatal heart tissues, and human fetal heart tissues (Supplementary figure 1b and c). The
representative cardiac structural genes cardiac troponin T (TNNT2, also known as cTNT)
and myosin heavy chain (MYH6/7, also known as α/βMHC) were most highly expressed in
all of these samples and thus were determined targets for MBs. Based on the qRT-PCR
results, we designed five MBs (Table 1) targeting unique sites in TNNT2 or MYH6/7
mRNA in both mouse and human using design rules determined by previous
publications30, 31 and BLAST searches to ensure uniqueness. These MBs were synthesized
with a Cy3 fluorophore or a FAM fluorophore at the 5′ end and a Black Hole Quencher 2 or
a Black Hole Quencher 1 at the 3′ end as specified in Table 1. We quantified beacon
fluorescence signal when hybridized to perfectly complementary and mismatched targets by
incubating 500 nM MBs with targets of increasing concentrations (100 - 500 nM). MB
signal was recorded using a microplate reader and normalized by the signal in wells with
MB only (Supplementary figure 2). All MBs displayed a linear response to increasing
concentrations of complementary target and a low response to mismatched targets.
In order to determine the most efficient transfection method to deliver MBs into living cells,
we compared the following six techniques: Streptolysin O32, Lipofectamin 200033,
Lullaby34, nucleofection35, electroporation36 and microinjection37. To quantify the delivery
efficiency, we fabricated a non-specific MB which has a non-specific sequence with FAM
dyes conjugated to both 5′ and 3′ ends, allowing the probe to fluoresce regardless of its open
or closed conformation. We delivered the non-specific MB into various cell lines including
an immortalized mouse CM cell line, HL-1 CMs 24, smooth muscle cells (SMCs), mouse
embryonic fibroblasts (MEFs) and mouse embryonic stem cells (mESCs). Flow cytometry
analysis demonstrated that regardless of the cell type, nucleofection consistently delivered
MBs into > 95% of the cells, showing the highest delivery efficiency (Supplementary figure
3 and part of data not shown).
We systematically determined the sensitivity of MBs designed to target CM-specific
mRNAs. As a positive control, we used HL-1 CMs. We independently confirmed the CM
identity of HL-1 CMs by flow cytometry, showing that 97.2% of cells expressed Tnnt2
(Supplementary figure 4). Each of the candidate MBs targeting TNNT2 or MYH mRNA
was delivered into HL-1 CMs by nucleofection and the efficacy was analyzed by flow
cytometry. Among the 5 MBs (TNT1, −2, −3 and MHC1, −2) examined, the MB designated
as MHC1-MB yielded the highest rate of MB-signal positive cells (98.9%) (Figure 3A).
To determine the specificity of the MHC1-MB, a ‘random’-sequence MB (‘random beacon’)
which has a 16-base target sequence that does not match any sequence in the mouse or
human genome, was delivered as a negative control31 and displayed negligible fluorescence
in HL-1 CMs (Figure 3B), ruling out the possibility that the fluorescence signal from
MHC1-MB was due to nonspecific interactions and/or probe degradation by endonucleases.
To further verify the specificity of the MHC1-MB, we delivered MHC1-MB into SMCs,
mouse aortic endothelial cells (mECs), mouse cardiac fibroblasts (mCFs) and mESCs, which
are the most likely contaminating cell types in cardiomyogenically differentiated PSC
cultures (Supplementary figure 5). Flow cytometry analysis showed that < 3% of these cells
displayed a detectable fluorescence signal. These results suggest high sensitivity of the
MHC1-MB for CM-lineage cells.
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Purification of mESC-derived CMs
Next, we investigated whether this MB can be useful for isolating CMs from differentiating
mouse PSCs. We first established an embryoid body (EB)-mediated system to efficiently
differentiate mESCs into CMs (Figure 4A). In brief, undifferentiated mouse ESCs (J1)
maintained on STO feeder cells were enzymatically detached to form EBs, which were
cultured for 5 days and plated on a fibronectin-coated dish for CM differentiation. After 3-4
days of differentiation in the presence of ascorbic acid (50 μg/ml)20, spontaneously beating
clumps began to appear (Supplementary movie 1). Flow cytometry analysis demonstrated
that the percentage of Tnnt2-positive cells were 13.4% and 47.1% at days 4 and 9,
respectively (Figure 4B). Immunostaining further demonstrated that cells dissociated from
beating clumps displayed Tnnt2, Tnni3 and Actn2 (or α-sarcomeric actinin), confirming
their CM nature (Figure 4C). The results with mouse iPSCs were similar (data not shown).
After establishing the differentiation system, we attempted to isolate CMs from
differentiating mESCs using MBs. The differentiating mESCs at day 9 were nucleofected
with MHC1-MB and subjected to FACS-sorting. The percentage of cells positive for
fluorescence signal from MHC1-MB was 49.2 ± 4.8% (Figure 4D). There was significant
agreement between the detection rate of CMs using antibody-based (47.1% Tnnt2-positive
cells) and MB-based (49.2% MHC1-MB-positive cells) flow cytometry results, supporting
the specificity of MHC1-MB. Fluorescent microscopic imaging also confirmed these results
(Supplementary figure 6). Next, cells were FACS-sorted using MHC1-MB and 98.4% of the
sorted MHC1-MB-positive cells exhibited Tnnt2 in flow cytometry (Figure 4E).
Immunocytochemistry verified that virtually all sorted MHC1-MB-positive cells expressed
Tnnt2 and Actn2 (Figure 4F). qRT-PCR analyses demonstrated that these sorted cells
expressed 2 to 6-fold higher levels of Tnnt2, Myh6, Myh7 and Myl2 compared to the pre-
sorted cells (Figure 4G). Genes representing other lineages were either expressed at
negligible levels (Acta2, Ddr2, Gata1 and Sox17) or were non-detectable (Pecam1, MyoD
and Neuro D) in the sorted cells (Figure 4G and data not shown). Importantly, these sorted
cells showed spontaneous contraction over 2 weeks suggesting that these MB-based purified
CMs were functional (Supplementary movie 2). In this movie, we intentionally selected
areas where individual CMs were contracting to demonstrate functionality of CMs at an
individual level.
Purification of hESCs-derived CMs
Similarly, we investigated the utility of MB-based cell sorting for human PSC-derived CMs.
We developed a novel four-step protocol for differentiating hPSCs into CMs (Figure 5A). In
phase 1, undifferentiated hESCs (H1) were directly transferred onto Matrigel-coated plates
and cultured as a monolayer under mTeSR® media (Stem Cell Technology) for cell
expansion. Next, to induce mesodermal differentiation, several combinations of mesodermal
inducers were tested and compared by qRT-PCR using mesodermal markers including T (or
BRACHYURY) and KDR. We found that a combination of BMP4 (10ng/ml), Activin A (3ng/
ml), and FGF2 (5ng/ml) was the most efficient for mesodermal differentiation
(Supplementary figure 7a). To induce cardiac lineage differentiation in phase 3, we tested
four different methods1, 3, 20, 38 and found that supplementation with conditioned media
produced by mouse endodermal cell line END-2 induced the highest expression of cardiac
lineage markers such as NKX2-5, TNNT2, MYH6 and −7 (Supplementary figure 7b).
Finally, in phase 4, continuous treatment with a β-adrenergic receptor agonist, isoproterenol,
for as short as 4 days efficiently generated spontaneously beating CMs (Supplementary
movie 3).
Flow cytometry analysis demonstrated that the percentage of TNNI3-positive cells were
10.2% and 43.1% at days 9 and 13, respectively (Figure 5B). We delivered the MHC1-MB
to the cardiomyogenically differentiated hESCs at day 13 in phase 4. Flow cytometry
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analysis showed that the percentage of cells positive for MHC1-MB signal was 46.3%
(Figure 5C). These MHC1-MB treated cells were sorted by FACS, and 97.6 ± 1.4% of the
sorted MHC1-MB positive cells exhibited TNNI3 expression in flow cytometry analysis
(Figure 5D). Almost all cells showed CM-like morphology and stained positive for TNNT2
and TNNI3 by immunocytochemistry (Figure 5E). qRT-PCR analyses showed a significant
increase in expression of CM-specific genes (TNNT2, MYH6, MYH7, and MYL2) and
decrease in expression of genes specific for SMCs (CALPONIN), fibroblast (THY1), skeletal
myocyte (MYOD), neural lineage cells (NEUROD), and EC (PECAM1), suggesting
enrichment of CMs and elimination of other lineage cells by cell sorting with the MB
(Figure 5F-G).
Stable action potentials (APs) were recorded from CMs that were purified via MHC1-MB
and cultured for 7-14 days after FACS-sorting. Three major types of APs were observed,
nodal-like (6 of 46), atrial-like (11 of 46) and ventricular-like (29 of 46) APs (Figure 5H,
Table 3). These results indicate that purified cells via a CM-specific MB are
electrophysiologically intact, functional CMs and can maintain these characteristics in
culture.
Purification of CMs from hiPSCs
We further determined the utility of MHC1-MB for isolating CMs from differentiating
hiPSCs (BJ1)22. Our differentiation system for CMs from hESCs was successfully applied
to hiPSCs, yielding 40.7% of TNNI3-positive CMs at day 13 (Figure 6A, B). MHC1-MB
was delivered into the differentiating hiPSCs at day 13 and the percentage of cells positive
for MHC1-MB analyzed by flow cytometry was 45.5% (Figure 6C). FACS sorting based on
MB signal resulted in enrichment of TNNI3-positive cells to 97.2 ± 1.9% (Figure 6D).
Almost all the sorted cells stained positive for TNNI3 or TNNT2 in immunostaining (Figure
6E). qRT-PCR again showed about a 3- to 7- fold increase in CM-specific gene expression
and substantial reduction or negligible levels of other lineage gene expression (Figure 6F).
The sorted MHC1-MB positive CMs showed spontaneous contraction (Supplementary
movie 4) and rhythmic calcium oscillations (Figure 6G and Supplementary movie 5). These
data suggest that the MHC1-MB-based purified CMs are functional CMs. Taken together,
our results clearly support the notion that MBs targeting CM-specific mRNA in live cells
allow isolation of functional CMs from differentiating mouse and human PSCs with high
specificity and efficiency.
Engraftment and improvement of cardiac function after implantation of purified CMs
To determine the behavior and effects of MB-based purified CMs in ischemic myocardium,
purified or unpurified CMs derived from mESCs or the same volume of PBS were injected
into the myocardium after induction of MI in mice. Echocardiography was performed
weekly to measure cardiac remodeling and function. One week later, however, in the mice
receiving unpurified CMs, a distinct mass was observed in the left ventricular lumen of the
hearts, which grew over 4 weeks (Figure 7A, B) Post-mortem examination at 3-4 weeks
revealed tumor masses in 11 out of 12 mice. By careful gross examination, tumors invaded
internally into myocardium and externally into the pericardium (Figure 7B, C). Cardiac
tissues were fixed and stained with hematoxylin and eosin (H&E). Microscopic examination
revealed that all tumors consisted of structures derived from all three embryonic germ
layers, indicating teratomas (Figure 7C). However, we did not detect tumors in any of the
mice receiving MB-based purified CMs or PBS over the same follow-up period by
echocardiographic or histologic examination. Tumor formation in unpurified-CM injected
mice did not allow appropriate functional comparison between mice receiving unpurified-
and purified CMs. However, purified CM-injected mice showed a higher ejection fraction
than PBS-injected mice (Figure 7D), indicating improved cardiac function. We next
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conducted immunohistochemistry for cardiac tissues injected with purified CMs. Confocal
microscopic examination demonstrated that injected CMs (DiI-positive) were engrafted as
clusters, survived robustly for 4 weeks and expressed representative CM proteins (Figure
7E). Taken together, these results suggest that injected MB-purified CMs are integrated into
ischemic myocardium and are functional in vivo.
Discussion
In the present study, we have described a highly specific and efficient method for purifying
CMs from differentiating mouse and human PSCs by directly targeting mRNA of CM-
specific genes. By using a MB targeting the mRNA of MYH 6 and 7 followed by FACS
sorting, we were able to enrich a population made up of more than 97% CMs from
differentiating PSCs. Their identity as CMs was verified by a series of experiments
including flow cytometry, immunocytochemistry, and qRT-PCR. Importantly, these purified
CMs displayed spontaneous beating upon further culture and demonstrated stable APs and
Ca2+ oscillation in electrophysiological studies. When injected into infarcted heart, MB-
purified CMs were integrated and survived robustly for 4 weeks in post-MI hearts, showing
improved cardiac function without forming tumors. On the other hand, mice injected with
unpurified CMs developed teratoma. These results support that MB-based isolated CMs are
pure and functionally intact CMs and CM purification is necessary for cell therapy.
Despite continuous improvements of current CM differentiation protocols, the resulting
differentiated cell populations still contain a considerable percentage of non-CMs. Hence,
one of the major challenges in recent years has been to develop stable isolation techniques
that allow scalable purification of CMs. Recently, three studies employing FACS-based CM
purification have attracted attention due to their sound scientific rationale, high purity and
clinical applicability. Among the first, a mitochondrial dye, TMRM has been suggested to
be useful for CM selection, enriching up to 99% as determined by the expression of Acnt2
( -sarcomeric actinin) in immunocytochemistry. This approach was based on the findings
that CMs have high mitochondrial content and can be purified via fluorescent dyes that label
mitochondria. However, two other following studies demonstrated that TMRM not only
failed to identify immature CMs early in differentiation culture14, but also detected non-
cardiogenic cells or undifferentiated hESCs as these cells uptake significant amounts of
TMRM6. In addition, two independent studies reported the identification of two surface
marker proteins; SIRPA and VCAM-1, and suggested their utility for isolating CMs from
differentiating hPSCs6, 14. To identify a candidate protein, Dubois et al screened a panel of
370 known commercially available antibodies and identified SIRPA as a specific marker for
CMs differentiating from hPSCs. Subsequently, isolation via FACS using an antibody
against SIRPA enriched cardiac precursors and CMs from hPSCs, yielding up to 98%
TNNT2+ cells. However, Elliott et al demonstrated that SIRPA+ cells expressed significant
amounts of smooth muscle marker genes such as ACTA2 and CNN1 and an endothelial cell
gene, CD34, bringing the utility of SIRPA as a sole marker for CM isolation into question.
This study also suggested that there are variations in the yield of cardiogenic marker
expression (NKX2-5) after further culture of sorted SIRPA+ cells, reaching as low as 2.8%
CMs depending on the isolation time and duration of culture. Furthermore, NKX2-5+ cells
did not express SIRPA, which raised concerns about specificity and sensitivity of SIRPA.
Thus Elliott et al identified another surface protein, VCAM1 through a transcriptome
analysis and employed it as an additional marker for isolating CMs. However, FACS sorting
with both SIRPA and VCAM1 antibodies was only able to enrich CMs ranging from 55 to
95% purity. Moreover, since both proteins are known to be expressed in other cell types, the
possibility of contamination with non-CM cells even after purification with SIRPA and
VCAM1 may be a critical issue14, 39.
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The MB-based CM purification strategy has a number of unique advantages in comparison
with previously reported CM purification methods. First of all, by directly targeting specific
intracellular mRNA, there is no need to make extensive efforts to identify surface proteins
for cell isolation using the corresponding antibodies 14, 40, 41. Secondly, MB-based cell
purification minimizes contamination of other cells by using MBs designed to hybridize
with unique sequences in the mRNAs of interest specifically expressed in the target cell
type6, 14, 42, 43. While significant efforts have been made to identify SIRPA and VCAM1 as
cell-surface markers for CMs, both SIRPA and VCAM1 are expressed in other organs such
as brain and lung, raising questions of the utility of these surface markers in a range of
differentiation systems. Another advantage of MB-based purification method is its
application to any species. It allows expanding the research scope with any desired cells.
Since SIRPA is not highly expressed in the mouse, its usage is limited to human cells. In
contrast, the MB-based method allows isolation of virtually any cell due to unlimited
accessibility of MBs to intracellular mRNA. Therefore, in addition to CMs, the MB based
sorting technique described here can be broadly applied to the isolation of other cell types
such as neural-lineage cells or islet cells, which are critical elements in regenerative
medicine but do not have specific surface proteins identified to date.
Our cell transplantation study provides an important insight into the necessity of purified
CMs for cardiac cell therapy. An unexpectedly high rate of tumors developed in mice
receiving unpurified mouse ESC-derived CMs. Although unpurified, these cells were
differentiated into the cardiac lineage and ~50% of cells were CMs. To date, a few studies
reported syngeneic or allogeneic transplantation of unpurified mESC-derived CMs into
infarct heart and all demonstrated tumor formation in hearts44, 45. Our study clearly
demonstrated that purified CMs do not form tumors and this purification process is a pre-
requisite for cardiac cell therapy with PSCs. Similar cardiac cell therapy studies were
conducted with human PSC-derived CMs and many of them showed functional
improvement with no tumor formation albeit utilizing non-purified cells 46, 47. However,
these studies might have underestimated tumorigenecity because xenogeneic transplantation
can induce engrafted cell death by immune reaction, particularly those non-cardiogenic cells
which are not aggregated.
To ensure that MBs were safe and effective to use in target cells, we carried out several
experiments to determine cell viability and functionality immediately and several days after
delivery of MBs. MBs were minimally disruptive as the results did not differ significantly
between hPSC-CMs and control cells in the assays performed. MBs usually degrade within
an hour 16-19, 31, so cell viability or cell fate change is not a serious concern. In addition, to
confirm their specificity, we carried out extensive testing to ensure that the MB signal was a
robust indicator of CMs based on the binding of the probe to MYH6/7. We tested the MBs
in solution with synthetic target oligonucleotides that varied from the ideal sequences by 6
bp, the closest that a BLAST search through the human transcriptome predicted that we
would see. None of the MBs used in the study increased their fluorescence by more than
50% even when incubated with excess target sequence.
The purified hPSC-derived CMs sorted via MBs will be enormously useful for clinical
applications as well as pre-clinical studies. A major obstacle to employing cells
differentiated from hPSCs for clinical applications is potential tumorigenicity or aberrant
tissue formation after cell transplantation41. By eliminating unwanted cells, this technology
will advance the utilization of hPSC-derived CMs. Moreover, mechanistic studies, drug
discovery, and disease modeling with non-pure PSC-derived CMs, although attempted
previously, can be inaccurate due to the effects of non-cardiomyogenic cells. This
purification technique in combination with CMs generated from patient-specific hiPSCs will
be of great value for drug screening and disease modeling as well as cell therapy.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Structure of CM-specific MBs. (A) Molecular dynamics model of a MB in the closed/
unbound conformation. The proximity of the 5′ Cy3 dye and the 3′ BHQ is small enough to
allow FRET quenching. (B) Molecular dynamics model of a MB in the open/bound
conformation. The distance between the 5′ Cy3 dye and the 3′ BHQ increases greatly to
prevent dye quenching.
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Figure 2.
Overall strategy to enrich hPSC-derived CMs using MBs targeting CM-specific mRNA.
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Figure 3.
Characterization of CM-specific MBs. (A) Flow cytometry results of five different MBs
designed to detect TNNT2 or MYH mRNAs on HL-1 CMs. MHC1-MB shows highest
detection rate. N = 3. (B) Flow cytometric analysis of HL-1 CMs treated with random versus
MHC1-MBs. The numbers represent the percentages of MB-positive cells. N = 3.
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Figure 4.
Purification of cardiomyocytes from differentiating mESCs using CM-specific MBs. (A) A
schematic of the protocol used for differentiating mESCs to the cardiac lineage. (B) Percent
expression of Tnnt2 at day 4 and 9 during mESC differentiation into CMs. N = 3. (C)
Immunocytochemistry results of mESC-derived CMs at day 9 for Tnnt2, Tnnt3 and Actn2.
Scale bars, 20 μm. (D) Flow cytometry analyses of MHC1-MB signals in mESC
differentiation culture at day 9. N = 6. (E) Flow cytometry analysis of Tnnt2 expression in
the mESCs sorted with MHC1-MB and FACS at the differentiation day 9. N = 3. The
numbers represent the percentages of MB-positive cells (D, E). (F) FACS-sorted MHC1-
MB-positive cells exhibit Tnnt2 and Actn2 in immunocytochemistry. Scale bars, 20 μm. (G)
qRT-PCR analyses showing difference in gene expression levels between mouse tail tip
fibroblasts (MTTF), and pre-sorted and post-sorted mESCs. CM genes, Tnnt2, Myh6, Myh7
and Myl2 were significantly enriched in post-sorted cells with MHC1-MB and non-cardiac
lineage genes (Acta2, Ddr2, Gata1 and Sox17) were substantially reduced compared to the
pre-sorted cells. Y axis represents relative mRNA expression of target genes to GAPDH. *P
< 0.05 compared to pre-sorted group. N = 3.
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Figure 5.
Purification of cardiomyocytes from differentiating hESCs by cell sorting via MB and
FACS. (A) A schematic of the protocol to differentiate hPSCs to the cardiac lineage. (B)
Percent expression of TNNI3 at day 9 and 13 determined by flow cytometry during hESC
differentiation into CMs. N = 3. (C) Flow cytometry results of MHC1-MB-positive cells in
hESC differentiation culture at day 13. N = 6. (D) Flow cytometry results showing TNNI3
expression of FACS-sorted hESCs at day 13 of differentiation after applying MHC1-MB.
The numbers represent the percentages of MB-positive cells (C, D). N = 3. (E)
Immunocytochemistry for TNNI3, and TNNT2 on MHC1-MB-positive cells sorted from
hESC cultures. Scale bars, 20 μm. (F) mRNA expression levels of cardiac and non-cardiac
genes measured by qRT-PCR. Comparisons were made for HDF, pre-sorted hESCs at day
13 and post-FACS sorted cells at day 13 using MHC1-MB. CM genes (TNNT2, MYH6,
MYH7 and MYL2) were significantly higher in the sorted hESCs compared to the pre-
sorted hESCs and HDF. Expression of the non-cardiac lineage genes (PECAM1,
CALPONIN, THY1, MYOD and NEUROD) was significantly lower in the sorted cells
compared to others. Y axis represents relative mRNA expression of target genes to GAPDH.
*P < 0.05 compared to pre-sorted group. N = 3. (G) mRNA expression levels of cardiac
genes from both MHC1-MB positive and negative cells measured by qRT-PCR. (H) Action
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potentials of the MHC1-MB-positive CMs. Shown are representative configurations of the
nodal- (top), atrial- (middle), and ventricular (bottom) action potentials.
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Figure 6.
Purification of cardiomyocytes from differentiating hiPSCs by cell sorting via MB and
FACS. (A) A schematic of the protocol to differentiate hiPSCs to the cardiac lineage. (B)
Percent expression of TNNI3 at day 9 and 13 during hiPSC differentiation into CMs
determined by flow cytometry. N = 3. (C) Flow cytometric analysis of MHC1-MB signals in
hiPSC differentiation culture at day 13. N = 6. (D) Flow cytometric results showing TNNI3
expression of FACS-sorted hiPSCs at day 13 of differentiation after applying MHC1-MB.
The numbers represent the percentages of MB-positive cells (C, D). N = 3. (E)
Immunocytochemistry for TNNI3, TNNT2 on MHC1-MB-positive cells sorted from hiPSC
cultures. Scale bars, 20 μm. (F) mRNA expression levels of cardiac and non-cardiac genes
measured by qRT-PCR. Comparisons were made among human dermal fibroblast (HDF),
pre-sorted hiPSCs at day 13, and MB-based FACS-sorted hiPSCs at day 13. Y axis
represents relative mRNA expression of target genes to GAPDH. *P < 0.05 compared to
pre-sorted group. N = 3. (G) Calcium imaging of MHC1-MB-positive CMs sorted from
hiPSCs. Left panel is a confocal scan of representative cells loaded with Fluo-4 AM, with
magnification of line-scanned region indicated with red dashed line (white scale bars 20μm,
legend shows increasing calcium levels with blue being low calcium). Right panel is a time-
course of [Ca2+]I, measured at line scan region in cell pictured and paced at 0.5hz by field
stimulation. [Ca2+] is plotted as fluorescence intensity normalized to baseline (F/F0).
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Figure 7.
Transplantation of unpurified and purified CMs into a mouse model of acute myocardial
infarction. (A) Serial echocardiography demonstrated a growing left ventricular mass at 1
week (left) and 4 weeks (right) in the mice receiving unpurified mESC-derived CMs. (B)
Images of excised hearts previously injected with unpurified or purified mESC-derived
CMs. (C) H&E staining of whole cardiac sections demonstrated infiltrative growth of
hypercellular tumors surrounding the heart and protruding into the cardiac lumen. H&E
staining revealed cell derivatives of all three embryonic germ layers: entoderm (left),
mesoderm (middle), and ectoderm (right), indicating teratomas. (D) Improvement of cardiac
function of mice transplanted with MB-purified CMs derived from mESCs. Ejection fraction
(EF: left) and Fractional shortening (FS: right) were significantly higher in the purified-CM-
treated group compared to PBS-treated group measured by echocardiography. Repeated-
measures ANOVA was used for statistical analyses. *P < 0.05. N = 5 - 10 per group. (E)
Confocal microscopic images showed that the transplanted Dil-labeled MB-purified CMs
(red fluorescence) express Myh6/7 (green), indicating engraftment and integration of
transplanted CMs in the MI hearts. Scale bars, 100μm.
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Table 1
The list of MBs and parameters.
Beacon
Name Target Sequence Beacon Sequence
Target
TEM
(°C)
TNT1 CCCAAGATCCCCGATGGAGAGAG TACCCTCTCTCCATCGGGGATCTTGGGTA 68.1
TNT2 AGAACCGCCTGGCTGAAGAGA CCCTCTCTTCAGCCAGGCGGTTCTGAGGG 68.4
TNT3 GAACAGGAGGAAGGCTGAGG ATCCTCAGCCTTCCTCCTGTTCGAGGAT 64.8
MHC1 GTGAAGAAGAAGATGGAGG CCTCCATCTTCTTCTTCACGGAGG 57.5
MHC2 AAGAGCCGGGACATTGGTGCCAA TTGGCACCAATGTCCCGGCTCTTGCCAA 71.4
The in silico description of the MBs synthesized for the study. The target Tm category describes a measure of the predicted affinity for the 20 bp
sequence specific loop for the indicated target sequence.
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Table 2
Primer sequences used for RT qPCR analysis.
Primer sequences used qRT-PCR analysis (mouse)
GENE FORWARD 5′-3′ REVERSE 5′-3′
Gapdh TGTGATGGGTGTGAACCACGAGAA
CATGAGCCCTTCCACAATGCCAA
A
Sox17 ACCTACACTTACGCTCCAGTC GCCGTAGTACAGGTGCAGAG
Kdr AGGCCC ATTGAGTCCAACTACACA
ATGTCTGCATGGTCCCATACTGG
T
Nkx2-5 TGGGTCTCAATGCCTATGGCTACA
GACGCCAAAGTTCACGAAGTTG
CT
Gata4 CACGCTGTGGCGTCGTAAT CTGGTTTGAATCCCCTCCTTC
Tbx5 TGGCTGAAGTTCCACGAAGTG TTTGGGATTAAGGCCAGTCAC
Tnnt2 TCACAACCTGGAGGCTGAGAAGTT
TCATCTATTTCCAACGCCCGGTG
A
Myh6 AGCTGACAGGGGCCATCAT ACATACTCGTTCCCCACCTTC
Myh 7
TGCCAATGACGACCTGAAGGAGA
A
TCTTCTGGTTGATGAGGCTGGTG
T
Myl2
AGATGCTGACCACACAAGCAGAG
A
TCCGTGGGTAATGATGTGGACC
AA
Myl7 AAGGGAAGGGTCCCATCAACTTCA
AACTTGTCTGCCTGGGTCATGAG
A
Neurod GACGGGGTCCCAAAAAGAAAA GCCAAGCGCAGTGTCTCTATT
Pecam TCTATGACCTCGCCCTCCACAAA
GAACGGTGTCTTCAGGTTGGTAT
TTCA
Cdh5 TGGAGAAGTGGCATCAGTCAACAG TCTACAATCCCTTGCAGTGTGAG
Gata1 TGTCCTCACCATCAGATTCCA TCCCTCCATACTGTTGAGCAG
Myod1 CCACGACCACCTCTCAGAAC GACAGGACAGTATGCAGTGGA
Ddr2 ATGATCCCGATTCCCAGAATGC CATATTTGGCAGCCGTGGATT
Acta2 CATGTACGTCGCCATTCAAGC TTGATGTCTCGCACAATTTCTCT
Primer sequences used qRT-PCR analysis (Human)
GENE FORWARD 5′-3′ REVERSE 5′-3′
GAPDH AGGTGGTCTCCTCTGACTTCAACA GACAAAGTGGTCGTTGAGGGCAAT
OCT4 ATGCATTCAAACTGAGGTGCCTGC CCACCCTTTGTGTTCCCAATTCCT
T TGTCCCAGGTGGCTTACAGATGAA GGTGTGCCAAAGTTGCCAATACAC
KDR ACTTTGGAAGACAGAACCAAATTASTCTC TGGGCACCATTCCACCA
MESP1 AGCCCAAGTGACAAGGGACAACT AAGGAACCACTTCGAAGGTGCTGA
NKX2-5 ACCTCAACAGCTCCCTGACTC ATAATCGCCGCCACAAACTCTCC
TBX5 ACAAAGTGAAGGTGACGGGC GGGGACCACGGGATATTCTT
TNNT2 TTC ACC AAA GAT CTG CTC CTCGCT
TTATTACTGGTGTGGAGTGGGTG
TGG
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Primer sequences used qRT-PCR analysis (Human)
GENE FORWARD 5′-3′ REVERSE 5′-3′
MYH6 TCA GCT GGA GGC CAA AAG TAAAGG A
TTCTTGAGCTCTGAGCACTCGTC
T
MYH7 TCGTGCCTGATGACAAACAGGAGT ATACTCGGTCTCGGCAGTGACTTT
MYL2 TGTCCCTACCTTGTCTGTTAGCCA ATTGGAACATGGCCTCTGGATGGA
MYL7 ACATCATCACCCATGGAGACGAGA GCAACAGAGTTTATTGAGGTGCCC
NEURO
D TCCCATGTCTTCCACGTTAAGCCT
CATCAAAGGAAGGGCTGGTGCA
AT
PECAM
1 TTCCTGACAGTGTCTTGAGTGGGT
TTTGGCTAGGCGTGGTTCTCATC
T
ACTA2 AATACTCTGTCTGGATCGGTGGCT ACGAGTCAGAGCTTTGGCTAGGAA
MYH11 GGTCACGGTTGGGAAAGATGA GGGCAGGTGTTTATAGGGGTT
MYOD1 CGCCATCCGCTATATCGAGG CTGTAGTCCATCATGCCGTCG
DDR2 ACCAGCCATTTGTCCTGACTCTGT ATCACTCGTCGCCTTGTTGAAGGA
THY1 ATACCAGCAGTTCACCCATCCAGT ATTTGCTGGTGAAGTTGGTTCGGG
ACTA2 AATACTCTGTCTGGATCGGTGGCT ACGAGTCAGAGCTTTGGCTAGGAA
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Table 3
Action potential properties in MB-based-purified CMs derived from hESCs.
AP types Upstroke slope(mV/ms)
½ AP width
(ms)
Firing frequency
(Hz)
Nodal-like 85.9 ± 5.2 247 ± 11.7 0.66 ± 0.04
Atrial-like 102.8 ± 6.7 201 ± 13.1 0.63 ± 0.03
Ventricular-like 99.7 ± 7.4 286 ± 13.5 0.55 ± 0.12
APs were measured in a total of 46 MHC1-MB-positive CMs: nodal-like (6 of 46), atrial-like (11 of 46) and ventricular-like (29 of 46) APs were
identified.
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